Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells

Cancer Immunology Research

Volumn 3, Issue 4, 2015, Pages 356-367

  Frigault, Matthew J ^a   Lee, Jihyun ^a   Basil, Maria Ciocca ^a   Carpenito, Carmine ^a   Motohashi, Shinichiro ^b   Scholler, John ^a   Kawalekar, Omkar U ^a   Guedan, Sonia ^a,e   McGettigan, Shannon E ^a   Posey, Avery D ^a   Ang, Sonny ^c   Cooper, Laurence J N ^c   Platt, Jesse M ^a   Johnson, F Brad ^a   Paulos, Chrystal M ^d   Zhao, Yangbing ^a   Kalos, Michael ^a,f   Milone, Michael C ^a   June, Carl H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHIBA UNIVERSITY   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD3 ANTIGEN ZETA; CD8 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME B; IMMUNOGLOBULIN G4; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; LENTIVIRUS VECTOR; MESOTHELIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERFORIN; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CD3 ANTIGEN, ZETA CHAIN; CHEMOKINE; CYTOKINE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CELL POLARITY; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENGRAFTMENT; FEEDER CELL; GENE LOCUS; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STABLE EXPRESSION; TH1 CELL; TH22 CELL; TRANSCRIPTION INITIATION SITE; TUMOR GROWTH; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL PROLIFERATION; CYTOKINE INDUCED KILLER CELL; DRUG SCREENING; FEMALE; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LENTIVIRINAE; LYMPHOCYTE ACTIVATION; METABOLISM; NONOBESE DIABETIC MOUSE; OVARIAN NEOPLASMS; PROCEDURES; SCID MOUSE; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD3; CELL PROLIFERATION; CHEMOKINES; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MICE, INBRED NOD; MICE, SCID; OVARIAN NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962213143     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0186     Document Type: Article

References (52)

1. Jena B, Dotti G, Cooper L. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010;116:1035-44.
2. Bonini C, Brenner MK, Heslop HE, Morgan RA. Genetic modification of T cells. Biol Blood Marrow Transplant 2011;17:S15-20.
3. Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, et al. Considerations for the clinical application of chimeric antigen receptor (CAR) T cells: observations from a recombinant DNA advisory committee (RAC) symposium June 15, 2010. Cancer Res 2011;71:3175-81.
4. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen MC, Cooper LJ, et al. CARS on trackinthe clinic: report ofa meeting organizedbythe blood and marrow transplant clinical trials network (BMT CTN) sub-committee on cell and gene therapy. Washington D.C., May 18, 2010. Mol Ther 2011; 19:432-8.
5. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor - modified T cells in lymphoma patients. J Clin Invest 2011;121: 1822-5.
6. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-81.
7. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365: 725-33.
8. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3: 95ra73.
9. Finney HM, Lawson ADG, Bebbington CR, Weir ANC Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998;161:2791-7.
10. Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 1996;26: 2304-9.
11. Feldhaus AL, Evans L, Sutherland RA, Jones LA. A CD2/CD28 chimeric receptor triggers the CD28 signaling pathway in CTLL.2 cells. Gene Ther 1997;4:833-8.
12. Geiger TL, Nguyen P, Leitenberg D, Flavell RA. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 2001;98:2364-71.
13. Arakawa F, Shibaguchi H, Xu ZW, Kuroki M. Targeting of T cells to CEA-expressing tumor cellsbychimeric immune receptors witha highly specific single-chain anti-CEA activity. Anticancer Res 2002:4285-9.
14. Haynes NM, Trapani JA, Teng MWL, Jackson JT, Cerruti L, Jane SM, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002: 5780-6.
15. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor. Nat Biotechnol 2002;20:70-5.
16. Finney HM, Akbar AN, Lawson ADG Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004;172:104-13.
17. Gyobu H, Tsuji T, Suzuki Y, Ohkuri T, Chamoto K, Kuroki M, et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 2004;64:1490-5.
18. Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, et al. A functional role for CD28 costimulation in tumor recognition by singlechain receptor-modified T cells. Cancer Gene Ther 2004;11:371-9.
19. Teng MW, Kershaw MH, Moeller M, Smyth MJ, Darcy PK. Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther 2004;15:699-708.
20. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 2005;105:3087-93.
21. Pule MA, Straath of KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005;12: 933-41.
22. Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A 2005;102:19051-6.
23. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RLH T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005;174:7853-8.
24. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006;66:10995-1004.
25. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to Tregulatory cells. Leukemia 2006;20: 1819-28.
26. Shibaguchi H, Luo NX, Kuroki M, Zhao J, Huang J, Hachimine K, et al. A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer Res 2006;26:4067-72.
27. Teng MWL, Kershaw MH, Jackson JT, Smyth MJ, Darcy PK. Adoptive transfer of chimeric Fc(epsilon)RI gene-modified human T cells for cancer immunotherapy. Human Gene Therapy 2006;17:1134-43.
28. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13:5426-35.
29. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009;17:1453-64.
30. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360-5.
31. Lukens JN, VanDeerlin V, Clark CM, Xie SX, Johnson FB. Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease. Alzheimer's Dementia 2009;5:463-9.
32. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can ge integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001;167:6123-31.
33. Skibinski G, Skibinska A, James K. The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs. Immunology 2001;102:506-14.
34. Voehringer D, Koschella M, Pircher H. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood 2002;100:3698-702.
35. Yeh JH, Sidhu SS, Chan AC. Regulation of alate phase of Tcell polarity and effector functions by Crtam. Cell 2008;132:846-59.
36. + T-cell clone following retroviral transduction with the IL-15 gene. Blood 2007;109:5168-77.
37. Newrzela S, Cornils K, Heinrich T, Schlager J, Yi JH, Lysenko O, et al. Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes. Mol Med 2011;17:1223-32.
38. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan A, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigenreceptor mediate regressionofhuman disseminatedtumor. Cancer Res 2010;70:9062-72.
39. Huang X, Wilber AC, Bao L, Tuong D, Tolar J, Orchard PJ, et al. Stable gene transfer and expression in human primary T-cells by the Sleeping Beauty transposon system. Blood 2006;107:483-91.
40. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system. Cancer Res 2008;68:2961-71.
41. McGuire KL, Curtiss VE, Larson EL, Haseltine WA. Influence of human T-cell leukemia virus type I tax and rex on interleukin-2 gene expression. J Virol 1993;67:1590-9.
42. Good L, Maggirwar SB, Harhaj EW, Sun SC. Constitutive dephosphorylation and activation of a member of the nuclear factor of activated T cells, NF-AT1, in Tax-expressing and type I human T-cell leukemia virus-infected human T cells. J Biol Chem 1997;272:1425-8.
43. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporineresistant interleukin 2 gene expression. Mol Cell Biol 1987;7:4472-81.
44. Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 2014;124:1070-80.
45. Yu X, Fournier S, Allison JP, Sharpe AH, Hodes RJ. The role of B7 costimulation in CD4/CD8 T cell homeostasis. J Immunol 2000;164: 3543-53.
46. Goronzy JJ, Li G, Yu M, Weyand CM. Signaling pathways in aged T cells - a reflection of T cell differentiation, cell senescence and host environment. Semin Immunol 2012;24:365-72.
47. Nguyen P, Moisini I, Geiger T. Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function. Blood 2003;102:4320.
48. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 2015;3:125-35.
49. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-28.
50. Kochenderfer J, Wilson W, Janik J, Dudley M, Stetler-Stevenson M, Feldman S, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. Blood 2010;116:4099-102.
51. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012;119:3940-50.
52. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-recep-tor-transduced T cells. Blood 2012;119:2709-20.